Back consequential science.
Biotechnology, medical devices, consumer health and technology. A broad mandate, held together by one clear purpose.
SECOND NATURE / VENTURE CAPITAL
Capital for a
longer,
better life.
Where biotechnology, medicine, longevity and AI meet. A venture fund built around breakthrough science—and the founders turning it into human possibility.
01 / OUR INVESTMENT LENS01 — 08
Start with the underlying insight.
Target biology, defensible differentiation and the evidence that matters.
GENETIC INFORMATION
THE BLUEPRINT
01 / GENETIC INFORMATION
The language of life.
A blueprint. A question. The beginning of discovery.
A JOURNEY ACROSS SCALES · SCHEMATIC, NOT A BIOLOGICAL PATHWAYSCROLL ↓ · REVERSE ↑
DNA 01 / 08
From molecular insight
to meaningful human impact.
BIOTECH · MEDICINE · LONGEVITY · AISCROLL TO EXPLORE ↓
+ BIOLOGY, BUILT TO MATTER
CELL 04 / 08
Scientific depth.
A clear connection to human benefit.
01 / THE FUND
Investing in the
Vitality Economy.
Our mandate: companies that help people live longer, healthier and more fulfilling lives. Science with a direct connection to human benefit—and a substantial commercial opportunity.
Build around the breakthrough.
Support founders on indications, milestones, leadership and partnerships. Explore company creation around promising assets.
Connect judgment with capital.
Scientific and clinical expertise alongside investment discipline, commercial insight and hands-on company building.
OUR UNDERWRITING LENS
Credible evidence + Defensible differentiation + A realistic capital plan + Venture-return potential
02 / ANATOMY → INTELLIGENCE
Anatomy becomes
intelligence.
We start with a human perspective. We look deeper into the brain’s connections and the biological signals that become data. Our investment thesis brings anatomy, clinical insight and computational intelligence together—with a human purpose at every step.
Biological depthStart with the mechanismClinical relevanceDefine the human benefitCommercial disciplineBuild for the real world
HUMAN PERSPECTIVE / DIGITAL POSSIBILITY03
Two perspectives.
One shared vision.
A SHARED VISIONSCROLL TO EXPLORE
Visual concept · Not personal imaging or patient data
Portraits require an internet connection.Portrait source ↗
Company
ecosystem
NAVIKSAN HEALTHRadSherpaRapalogixZIÖRABIORAMICSVesalius
03 / INVESTMENT FOCUS
At the intersection
of what comes next.
Where biotech, medicine, longevity and AI meet. Four connected investment themes, evaluated through evidence, differentiation, clinical relevance and commercial opportunity.
THE INVESTMENT LENS / 01Better questions.
Better questions.
Better molecules.
A proposed focus on target biology, small molecules, peptides and translational platforms. The question is not only what a molecule can do—but what must be demonstrated before it becomes a medicine.
04 / COMPANY ECOSYSTEM
Scientific ambition.
Company-building perspective.
A connected view of clinical strategy, medical AI, drug discovery, reproductive science, regenerative biomaterials and longevity.
Featured companies illustrate leadership experience and owner-selected areas of interest. They are not presented as investments made by this fund. Each profile distinguishes the company’s work and the relevant relationship.
05 / PROPOSED FUND LEADERSHIP
Operating experience.
An investment perspective.
Healthcare company-building experience meets clinical insight, invention and a long-term perspective on human health.
SECOND NATURE / LEADERSHIP 01COMPANY BUILDERHEALTHCARE LEADER
Company building & commercialization
Brent Saunders
Healthcare leadership across pharmaceuticals, medical devices and consumer health. His experience includes Bausch + Lomb, Allergan, Forest Laboratories and Actavis. A co-founder and board member of Rapalogix Health.
SECOND NATURE / LEADERSHIP 02PHYSICIAN · INVENTOREDUCATOR
Clinical science & innovation
Pradeep Albert, M.D.
Musculoskeletal radiologist, physician-inventor and educator working across medical imaging, regenerative medicine and longevity. Founder of Naviksan Health and RadSherpa.
Leadership positioning follows the supplied firm concept. Formal roles and commitments remain subject to confirmation.
06 / INVESTMENT APPROACH
Find the insight.
Build the investment case.
A disciplined path from scientific insight to a company worth building. Milestone-led diligence, a realistic capital plan and a clear view of how adoption could be earned.
01 / DISCOVER
Start with the right question.
Identify a meaningful unmet need, a differentiated scientific insight and a plausible path to a product. Look for assets and founders worth building around—not just a compelling narrative.
A clear connection between mechanism and human benefit.
A view of reproducibility, differentiation and intellectual property.
A next experiment capable of changing the decision.
Our proposed investment framework. Development evidence, ownership strategy and capital requirements are evaluated for each opportunity.
07 / FOR INVESTORS
The long view.
The human return.
For investors who see opportunity in the convergence of biology, medicine and intelligent technology. Explore the mandate, the company-building philosophy and the questions behind our investment discipline.
Fund in development. Information requests begin a conversation, not a subscription.SCIENTIFIC INSIGHTCOMPANY BUILDINGDISCIPLINED CAPITAL
THE PURPOSELonger.
Better.Human possibility.
Better.Human possibility.
Building where biotech, medicine, longevity and AI meet? Tell us about your insight, your evidence and the next milestone that matters.
Your science.
Our next conversation.
Building at the intersection of biology, technology and human health? Bring the science. Bring the question. Let's explore what it could become.
Introduce a company, an emerging platform or an asset with the potential to become something important.
Prepare an introduction · No automatic submission